Making the (clinical) grade with adenoviral gene therapy vectors
β Scribed by Beth Hutchins
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 142 KB
- Volume
- 2
- Category
- Article
- ISSN
- 1087-8378
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Background Fusogenic membrane glycoproteins (FMG) such as the gibbon ape leukemia virus envelope (GALV) glycoprotein are potent therapeutic transgenes with potential utility in the gene therapy of gliomas. Transfection of glioma cell lines with FMG expression constructs results in f
Although adenoviruses are an attractive vehicle for gene transfer into tissues including various tumors, in vivo adenoviral administration elicits a neutralizing antibody response which eliminates or substantially reduces the efficacy of subsequent treatments. Transiently immunosuppressive strategie
## Abstract Insertional mutagenesis resulting in a leukaemiaβlike lymphoproliferative disease, as observed in the XβSCID (severe combined immunodeficiency) clinical trial using a Ξ³βretroviral vector that transferred a functional copy of the defective gene into hematopoietic precursor cells of affec